Following a needlestick exposure in Australia, with an initial HIV-negative result and hepatitis B immunity, when should HIV and hepatitis C serology be repeated?

Post-Needlestick Follow-Up Testing Schedule in Australia

For HIV testing, repeat at 6 weeks, 3 months, and 6 months post-exposure; for hepatitis C, test at 4-6 months (or HCV RNA at 4-6 weeks if earlier diagnosis desired). Since you are already hepatitis B immune, no further HBV testing is required.

HIV Follow-Up Testing

Perform HIV antibody testing at baseline (already done), 6 weeks, 3 months, and 6 months post-exposure 1. This 6-month window period ensures adequate time for antibody seroconversion, though most infections will be detected earlier with modern testing methods.

Key HIV Testing Considerations:

• Seek immediate medical evaluation if you develop any acute illness during the follow-up period that could be compatible with acute retroviral syndrome (fever, rash, lymphadenopathy, pharyngitis) 1
• If HIV post-exposure prophylaxis (PEP) was initiated, you should have been evaluated within 72 hours of exposure and monitored for drug toxicity for at least 2 weeks 1
• Use precautions to prevent secondary transmission during the entire 6-month follow-up period 1

Hepatitis C Follow-Up Testing

Test for anti-HCV antibodies and ALT at 4-6 months after exposure 1. This is the standard timeline that allows adequate time for antibody development.

Alternative Earlier HCV Testing:

• If you want earlier diagnosis, HCV RNA can be performed at 4-6 weeks 1, 2. This detects active viral replication before antibodies develop
• If anti-HCV testing is repeatedly reactive on enzyme immunoassays, confirm with supplemental tests 1
• European guidelines suggest monthly ALT monitoring for 4 months if early treatment during acute phase is being considered 2

Hepatitis B - No Further Testing Needed

Since you are already hepatitis B immune (documented vaccine response), no further HBV testing or intervention is required 1. Your existing immunity provides protection against HBV infection from this exposure.

Important Caveats:

• The actual transmission risk from needlestick injuries is very low, particularly in Australia where HIV and HBV prevalence among potential source populations is only 1-2%, though HCV prevalence can be 50-60% among injecting drug users 3
• Adherence to follow-up testing is critical - studies show approximately 97% of healthcare workers complete follow-up when properly counseled 4
• Document the exposure thoroughly and ensure the source patient's infectious status is known if possible 1
• While no post-exposure prophylaxis exists for HCV, early treatment of acute HCV infection with antivirals is highly effective if infection occurs 5, 6